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Abstract
The incidence of heart valve disease increases significantly with age.
Degenerative abnormalities associated with severe aortic stenosis and mitral and
tricuspid regurgitation are found in not less than 10% of the population aged ≥ 75
years. Surgical treatment has been considered for years to be the treatment of
choice. However, it was not uncommonly associated with high perioperative
morbidity and mortality due to frequent comorbidities and overall frailty
conditions of these patients. Conventional risk scores such as Society of Thoracic
Surgeons and European System for Cardiac Operative Risk Evaluation may
underestimate the risk of surgery in elderly patients, leading to inappropriate
surgical indication. On the other hand, at least 30% of patients with severe
conditions are left untreated due to prohibitive surgical risk. Interventional
procedures, which are in continuous development, may be actually considered
for high risk patients and, as recent results suggest, also for intermediate risk
patients.
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Core tip: Severe heart valve diseases are not uncommon in the elderly and often
treatment may be challenging due to high risks related both to relevant comorbidities and
the frailty condition of elderly patients. Although surgery is still the first choice for most
conditions, interventional strategies are emerging as a valid alternative both in high and
intermediate risk patients. Careful evaluation is needed for each individual patient in
order to establish a more appropriate strategy considering that the impact on the quality
of life may be more relevant in this population than the effects on survival, which is
already limited by decreased life expectancy related to ageing.
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INTRODUCTION
Progressive ageing of a population is associated with an increased prevalence of
chronic degenerative diseases. Among these, heart valve abnormalities represent an
important public-health problem leading to high morbidity and mortality. The Euro
Heart Survey on valve heart disease (VHD) published in 2003 included 5001 adults
from 25 countries suffering from moderate to severe heart valve disease[1].  Native
VHD was found in  about  4000  patients.  The  remaining had had previous  valve
surgery. Degenerative process was the main cause of aortic involvement and mitral
regurgitation  (MR).  Mitral  stenosis  (MS)  was  mainly  due  to  rheumatic  disease.
Incidence of valvular disease increased with age. Incidence of VHD was 6% for both
mitral and aortic disease in patients aged ≥ 75 years, while in younger patients (aged
< 64 years), the incidence was less than 1%. Importantly, according to the Survey,
more than 30% of subjects with severe, symptomatic, single VHD, usually elderly
with relevant comorbidities, did not undergo surgery.
More recently,  Nkomo et  al[2]  reported the results of echocardiographic exami-
nations in 11911 randomly selected adults who had been prospectively assessed in
three large population-based epidemiological studies[3-5]. Moreover, included in the
study were 16501 adults who were assessed in community by clinically indicated
echocardiography. In the first group, 615 patients (5.1%) had moderate or severe valve
disease.  There  were  no  gender  related  differences.  Prevalence  of  valve  disease
increased significantly with age from 0.7% in the group comprised of 18-year-olds to
44-year-olds  to  13.3%  in  the  group  of  those  75  years  and  older  (P  <  0.0001).  A
significant increase of VHD was reported for each increment of 10 years of ageing.
This was particularly evident for aortic stenosis (AS) (hazard ratio (HR) = 2.51; 95%
confidence interval (CI): 2.02 to 3.12; P < 0.0001). MR was the most frequent VHD in
elderly patients (9.3%) followed by AS (2.8%), aortic regurgitation (AR) (2.0%), and
finally MS (0.2%).
In the community group, valve disease was diagnosed in 1505 patients. Prevalence
of valve diseases increased considerably with age also in this group (0.3% in 18-44
years old, 11.7% in those aged ≥ 75 years). There was a trend that showed a lower rate
of diagnosis in women than in men. Both in in the population and in the community
study, valve disease was associated with an increased mortality risk ratio (RR) (1.36,
95%CI: 1.15–1.62;  P  = 0.0005 and respectively 1.75,  95%CI: 1.61–1.90;  P  < 0.0001).
Incidence of heart valve disease in 500 consecutive patients aged > 8 years referred to
our Center for hip fracture is reported in Figure 1.
Due  to  increased  life  expectancy  in  the  elderly  population,  AS  prevalence  is
expected to increase further. according to recent projections from The OxVALVE
population cohort study in the United Kingdom, the number of elderly people with
moderate or severe valvular heart disease will more than double by 2056[6].
A retrospective study from Scotland showed that among all patients hospitalized
from 1 January 1997 to 31 December 2005, a final diagnosis of non-congenital aortic
valve disease was made in a total of 19733 adults[7]. Discharge diagnosis was AS in
13220 (67.0%) and AR in 2807 (14.2%). Mixed aortic valve disease, or unspecified
aortic valve disease, occurred respectively in 699 (3.5%) and 3007 (15.2%). Elderly
patients, aged 80 and older, accounted for most of the patients included in the study.
More than half had died by 31 December 2006. The risk of death (and heart failure)
was 20% higher in AS in comparison to aortic insufficiency or mixed aortic valve
disease. Only 19.4% of patients included in the study had aortic valve replacement
during  follow-up,  three  out  four  for  AS.  Age,  female  gender,  and co-morbidity
influenced replacement rate.
Despite  the  relevance  of  VHD as  a  cause  of  heart  failure  and  death,  the  first
European  Heart  Valve  Disease  survey  demonstrated  that  the  awareness  and
knowledge of heart valve disease in the general population was alarmingly low, and
only 3.8% really knew what AS was[8]. Two years later, the second European Heart
Valve Disease survey showed a mild improvement in general knowledge of heart
valve disease in comparison to 2015. Despite this finding, the correct understanding of
AS decreased significantly (2015: 7.2% vs 2017: 3.8%; P < 0.001)[9].
Treatment of VHD in the elderly requires careful evaluation since other than the
effects on survival, already limited by decreased life expectancy related to ageing, the
impact on the quality of life should be considered a relevant aspect. In elderly people,
clinical outcome after surgical treatment is significantly influenced by concomitant
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Figure 1
Figure 1  Incidence of valve heart disease in 500 consecutive patients aged > 80 years referred for hip
fracture.
severe comorbidities  [diabetes  mellitus,  chronic  kidney disease,  cerebrovascular
disease,  and atrial  fibrillation (AF),  etc]  that  may impair  postoperative recovery,
leading to worse outcomes[10]. A multidisciplinary approach involving cardiologists,
interventional  cardiologists,  surgeons,  anesthesiologists,  and  geriatricians  may
improve the decisional process.
AORTIC VALVE
AS
Epidemiology and pathophysiology: In the elderly, degenerative AS is one of the
most common types of valvular heart disease. The prevalence of AS has been reported
to be between 12% and 26% depending on the diagnostic criteria employed[1,11]. In the
study by Lindroos et al[12], critical AS was defined as a valve area < 0.8 cm2 or velocity
ratio of < 0.35. In the 75- to 86-year-old group, the reported prevalence of disease was
2.9% (95%CI: 1.4% to 5.1%). Overall, 40% of patients with severe AS were considered
to  be  at  high  surgical  risk.  It  must  be  emphasized  that  although  AS  is  clearly
associated with adverse outcomes, even aortic sclerosis can create an increased risk of
cardiovascular morbidity and mortality mainly by its being a significant risk factor for
progression to AS. Degenerative calcific disease accounts for most cases of severe AS;
however, a large study reported that 22% percent of octogenarians presenting for
surgery for isolated AS had bicuspid valve disease[13-15].
Calcific  aortic  valve disease evolves over the years at  a different rate in every
subject. The development and progression of AS is at least in part related to active
processes that have pathophysiological mechanisms in common with atherosclerotic
disease[14].  First,  several  studies  suggested  that  calcific  degenerative  AS  and
atherosclerosis  have  common  risk  factors  such  as  age,  smoking,  hypertension,
hypercholesterolemia, diabetes mellitus, and metabolic syndrome[15-18]. Since valve
leaflets  may  have  anatomic  heterogeneity,  different  shear  stresses  may  lead  to
endothelial dysfunction at the ventricular surface of the valve. Second, the loss of
endothelial integrity allows lipid accumulation and cellular migration (inflammatory
cells, macrophages, and T cells) in the subendothelial matrix[19] with neurohormonal
activation [20 ].  Plaque-like  subendothelial  deposits  may  lead  to  downward
displacement and fragmentation of the subjacent elastic lamina. The osteoblast-like
activity of interstitial cells may be responsible for valvular calcification over time with
a decrease in leaflet mobility[21].
AR
Epidemiology and pathophysiology: Isolated AR is significantly less common than
pure AS. Degenerative and bicuspid aortic valve disease shows a different degree of
both regurgitation and left ventricular obstruction; however, stenosis is usually pre-
eminent. More frequently, AR is a consequence of aortic dilation and the deformation
of the annulus valve. Overall prevalence of significant native AR has been reported in
between  2.0% and 2.5% of  patients  70  years  to  83  years  of  age,  without  gender
differences[22,23] although smaller studies reported a higher incidence of up to 13%.
Age, aortic valve fibrocalcification, and female sex were considered independent
factors related to AR, while several studies failed to find a relationship with arterial
hypertension[24].
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Treatment of aortic valve diseases: Surgical aortic valve replacement (SAVR) has
been, for a long time, the treatment of choice for severe aortic valve disease. Improved
survival  and  quality  of  life  have  been  clearly  demonstrated  even  in  elderly
patients[25-27]. Nevertheless, a non-negligible number of elderly patients are considered
at very high or prohibitive risk for conventional surgical procedures, and about 30%
of symptomatic subjects will never undergo surgery[1].
Non-surgical options, in particular transcatheter aortic valve replacement (TAVR),
have developed as a suitable alternative to SAVR. In humans, the first transcatheter
aortic stent valve was implanted in 2002, using femoral vein access and a transeptal
approach[28]. In 2005, technical developments allowed for changing the approach to
the  transfemoral  artery[29].  Transapical  TAVR (TA-TAVR)  has  been  proposed in
patients with unsuitable vascular access. Several studies compared safety and efficacy
between  the  transfemoral  TAVR  (TF-TAVR)  and  TA-TAVR.  The  transfemoral
approach, whenever feasible, should be considered the preferable access route[30].
Initially, the indication for TAVR was limited to severely symptomatic AS with
high surgical risk according to validated risk scores [Society of Thoracic Surgeons
(STS) or European System for Cardiac Operative Risk Evaluation (EuroSCORE)]. At
present, indications for percutaneous treatment may be extended to intermediate risk
subjects. Nevertheless the use of STS-risk score (or EuroSCORE) may be misleading in
very old people (aged > 80 years) since a high risk of perioperative complications may
exist  due to overall  age and frailty per se[31-33].  Frailty,  limited functional capacity
according to Barthel scale, inadequate nutrition, and the need for non-cardiac surgery
(most frequently oncologic or orthopedic surgery) are good indicators for TAVR,
which allows a faster recovery and improved quality of life.
The randomized PARTNER 1B study first showed a decrease in death from any
cause and death from cardiovascular causes in patients who underwent TAVR vs a
conservative treatment[34]. The PARTNER 1A trial randomized 699 high-risk patients
with severe AS to TAVR (using transfemoral or the transapical approach) or SAVR[35].
Death from any cause at 1 year was similar in the two groups, while major vascular
complications (11.0% vs 3.2%, P < 0.001) and stroke (8.3% vs 4.3%, P < 0.05) were more
frequent in TAVR than in SAVR. At 2 years follow-up, TAVR was associated with an
increased late mortality mainly related to mechanical complications of the valve such
as paravalvular leak. With first generation devices, residual AR due to para-valvular
leaks was found postoperatively in about 20% of patients. Minimally invasive aortic
valve replacement was proposed to manage carefully selected patients with the aim of
decreasing permanent pacemaker implantation and other vascular complications that
would be critical to changing patient prognosis.
In the study by Hirji et al[36], 1028 octogenarians underwent isolated aortic valve
replacement between 2002 and 2015. Three hundred and six were treated by TAVR
and 722 by SAVR (344 conventional and 378 minimally invasive valve replacement).
Median follow-up was 35 mo. TAVR patients were relatively older (86.2 years vs 84.2
years) and in more cases had several co-morbidities. Operative mortality and mid-
term survival were similar for TAVR (regardless of approach), SAVR, and minimally
invasive aortic  valve replacement  after  adjustment  for  confounding factors.  The
median in-hospital length of stay was statistically higher for the SAVR group (P <
0.05). Independent predictors of mortality were age, class III/IV New York Heart
Association (NYHA), preoperative creatinine, severe chronic lung disease, and prior
cardiac surgery (all P < 0.05). The authors concluded that treatment decisions should
be  addressed  by  a  multi-disciplinary  heart  team,  taking  into  account  patient
comorbidities, frailty, and quality of life.
Recently were reported the results of the FRench Aortic National CoreValve and
Edwards (FRANCE-2) registry. In the study were included 2254 patients > 80 years of
age who underwent TAVR. Thirty-day and 1-year mortality were not significantly
different among patients aged 80 to 84 years, 85 to 89 years, and finally > 90 years
(10.3% vs 9.5% vs 11.2%; P = 0.53 and respectively 19.8% vs 26.1% vs 27.7%; P = 0.16)[37].
A recent study compared carefully selected patients > 90 years old, without many
comorbidities, vs younger patients who underwent TAVR. Major complications were
similar, and all-cause mortality at 30 days and 1 year was not statistically different
(2.9% and 12.5% in  patients  aged ≥  90  vs  2.8% and 12.3% in  patients  aged <  90,
respectively)[38].
The  effects  of  TAVR  were  evaluated  more  recently  in  low-intermediate  risk
populations. An Italian observational, multicenter, “real-world” study included 1300
patients in a propensity-matched population. The authors did not find significant
differences in mortality or major adverse cardiac and cardiovascular events between
SAVR and TAVR[39].
In the PARTNER 2A randomized trial, TAVR was compared with SAVR in 2032
intermediate-risk  patients.  The  primary  endpoints  were  all-cause  mortality  or
disabling stroke at 2 years. The authors did not find differences between groups.
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Although major vascular complications and paravalvular regurgitation were more
frequent in TAVR, surgical replacement was associated with higher rates of acute
kidney injury, severe bleeding, and new-onset AF[40].
The multicenter Surgical Replacement and Transcatheter Aortic Valve Implantation
trial  was a randomized,  clinical  trial  that  included 1746 patients  at  intermediate
surgical risk, of whom 1660 underwent TAVR or surgical operation[41]. The primary
endpoint, a composite of death from any cause or disabling stroke at 24 mo, was
12.6% in TVAR and 14% in SAVR respectively. On the basis of these results, 2017
American Heart Association/America College of Cardiology gave a IIa indication for
the TAVR procedure in intermediate surgical risk[42].
Data from studies of a low-risk group for surgery, showed that SAVR is still more
advantageous than TAVR. Rosato et al[43] reported that survival at 3 years was 72.0%
after TAVR and 83.4% after SAVR (P = 0.0015). Further studies with new generation
valve prostheses are necessary before expanding indications of TAVR in lower-risk
patients.
Effects  of  coronary artery disease:  Coronary artery disease (CAD) is  frequently
associated with AS, in particular in elderly patients[44]. The coexistence of CAD leads
to  a  worse  prognosis  for  AS  of  comparable  severity.  Surgical  treatment  allows
correction of valve disease and at the same time coronary revascularization. Data
regarding elderly subjects are limited. Less is known about the effects of CAD in
elderly patients undergoing TAVR.
To evaluate the effect of age on combined AVR and concomitant coronary artery
bypass graft (CABG), 452 consecutive patients (mean age 64 years) were divided into
three groups: Young (n = 114), middle-aged (n = 225), and elderly (n = 113). CAD was
more extensive in the elderly group. Only 62.8% of elderly patients had complete
myocardial revascularization in comparison to 94.1% and 76.2%, respectively, of the
other  two  groups  (P  <  0.05).  In-hospital  mortality  was  6.4%  in  the  elderly  in
comparison to 2.0% and 5.3%, respectively in the other groups. Freedom from cardiac-
related death at 12 mo and 60 mo was higher in young and middle-aged patients than
in elderly patients[45].
How CAD impacts patient survival following TAVR has been investigated by a
recent meta-analysis. Fifteen studies including 8013 patients were examined. The
median age of patients was 81.3 years, 46.6% were men, and 3899 (48.7%) had CAD.
All-cause mortality at 30 days post TAVR was not significantly different between
patients with and without CAD. All-cause mortality however was significantly higher
at 1 year in patients with CAD in comparison with patients without CAD (OR = 1.21;
95%CI:  1.07–1.36;  P  =  0.002).  These results  suggest  the need to revisit  the revas-
cularization strategies for concomitant CAD in patients with TAVR[46].
AS and MR
In the elderly, AS is frequently associated with concomitant MR (22%-48%). In severe
cases affecting both valves, surgical valve replacement has usually been considered
the treatment of choice. Data regarding elderly subjects is limited. In the study by Yu
et  al[47],  43  high-risk  patients  with  severe  AS,  aged  80  ±  6  years,  underwent
concomitant SAVR and mitral valve (MV) surgery. Nineteen (44%) had prior cardiac
surgery, and 39 (91%) were in congestive heart failure. Five patients (11.6%) died
during hospitalization or at 30 days. Mortality was 25% at 6 mo, 35% at 1 year, and
45% at 2 years. Patients often needed prolonged ventilation, and 10% developed new
renal failure requiring dialysis. When AS in patients at high or prohibitive surgical
risk is treated by percutaneous TAVR, concomitant significant MR usually is not
corrected[48,49]. Untreated MR is associated with a significant increase in mortality and
morbidity[50].
The recent availability of percutaneous devices for treating MV disease may offer
an alternative for the management of  MR after  TAVR[51].  Few limited case series
reported a procedural success (decrease of degree of MR < 2+) comprised between
92% and 100% for edge to edge MV repair with MitraClipTM (Abbott Vascular, Menlo
Park, CA, United States)[52]. Recurrent 3+ MR at 1 year however occurred in 21.4%.
One year survival rate was 66.5%.
In conclusion, concomitant MV surgery in patients with MV disease undergoing
aortic valve replacement did not give better results on long term survival than TAVR
without correction of MV regurgitation. Therefore, individual assessment should
guide procedural strategy in treating MR associated with severe AS.
MV
Epidemiology and pathophysiology
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Several conditions may damage the MV in older patients, such as degeneration of
valve leaflets, calcification of the mitral annulus commonly involving the posterior
leaflet, ischemia, and rheumatic heart disease.
Anatomo-functional  abnormalities  of  the  MV  apparatus  may  result  in  valve
stenosis  or,  more frequently,  regurgitation.  The most  common etiology of  MS is
rheumatic  heart  disease;  however,  it  is  not  common  that  the  disease  remains
undiagnosed up until an advanced age[53]. Degenerative MV annulus calcification is
more  frequent  in  the  elderly,  but  it  is  unclear  how  frequent  a  significant
hemodynamic  impact  might  be.  Functional  MS  related  to  massive  annular
calcification and reduced leaflet excursion has been reported in 2.5% to 18.0% of
elderly patients[54]. Degenerative MS accounted for 12.5% of MS cases according to
data  of  the  Euro  Heart  Survey[1].  The  severity  of  calcification  has  significant
implications for surgery. Debridement of the posterior annulus may be challenging,
and residual calcium may not allow adequate suturing of the MV prosthesis with the
risk of post-operative paravalvular regurgitation due to suture dehiscence. Moreover,
there is the non-negligible risk of extensive damage and posterior disruption of the
left ventricle and that of death.
In industrialized countries,  MR is  the most  frequent  valvular  heart  disease in
patients over the age of 65 years[1,2].  Elderly patients account for about 40% of all
patients with MR and 4.5% are over 80 years of age. Heart failure, arrhythmia, and
death may occur in patients with severe disease. Prevalence of moderate MR in the
Framingham study was 11.1% in men 70 years to 83 years of age[23]. In the study, no
information was reported regarding valve morphology.  Secondary MR has been
reported in about 25% of patients after myocardial infarction and in more than 50% in
heart failure with depressed ejection fraction.
Treatment
Etiology of MV regurgitation plays a relevant role in the decision-making process,
particularly in elderly patients. MV surgery is indicated only if the balance between
expected clinical improvement exceeds increased operative risk related to ageing and
comorbidities. Surgical treatment is clearly suggested by American guidelines for
patients  with  primary  valve  disease,  while  no  indications  are  provided by  ESC
guidelines[42,55].  A high operative mortality (15%) was reported by a recent meta-
analysis  including  5572  octogenarian  patients [ 5 6 ] .  Therefore,  a  careful
multidimensional preoperative evaluation is needed for risk stratification since STS
and EuroSCORE may effectively underestimate effective surgery related risks in
elderly, frail patients. Left ventricular dysfunction is more frequent with concomitant
CAD. Surgical revascularization increases the risk of both early and late mortality
after surgery.
Secondary MR in those aged > 75 years is likely to be more frequent than primary
valve disease. In this case, no clear indication for surgery exists as the clinical benefit
is  uncertain.  When concomitant  coronary artery  bypass  grafting is  not  planned,
surgical  intervention  may  be  recommended  only  in  patients  with  refractory
symptoms  after  optimization  of  medical  therapy  and  eventual  cardiac  resyn-
chronization therapy[57,58].
MV-repair  at  present  is  the  generally  accepted “gold standard” treatment  for
degenerative MV disease. Several studies demonstrated the superiority of repair over
MV replacement  (MVR)[59,60].  Patients  with extensive bi-leaflet  or  anterior  leaflet
prolapse  and  myxomatous  degeneration  without  extensive  calcification  are
considered good candidates for MV repair. Nevertheless, in elderly patients MV-
repair as suggested by administrative American databases was performed in less than
50%. Advanced age was as an independent predictor of valve replacement[61].
The  lower  technical  complexity  of  valve  replacement  with  shorter  cardio
pulmonary bypass times and decreased risk of failure with need of reintervention
may explain the lower rate of MV repair than expected in elderly patients. These
aspects are particularly relevant due the limited life expectancy of aged patients.
Nevertheless, MVR has a high short-term mortality of 25% to 30%, frequently due to
congestive heart failure possibly related to alteration of the left ventricular dimensions
and geometry.
Differences  in  long-term clinical  outcomes between surgery and conservative
management were evaluated by Kang et al[62] in 157 patients with severe MR aged ≥ 70
years. Median follow-up was 5.4 years. Surgery was associated with a lower mortality
(HR 0.31; 95%CI: 0.13 to 0.73; P = 0.007) other than with a decrease in overall cardiac
event (HR 0.26; 95%CI: 0.13 to 0.53; P < 0.001).
In a single center retrospective study in 2015, consecutive patients with moderate to
severe MR were divided into two groups[63]. Patients aged > 60 years (mean age 66.98
± 5.94 years) were considered as the elderly group (n = 680) and compared to patients
<  60  years  (control  group,  n  =  1061).  In  total,  308/680  elderly  MR were  denied
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surgery, which was much higher than the rate of denial observed in the control group
(45.29% vs 36.10%, P < 0.001). The factors associated with decreased probability of
undergoing  surgery  were  increased  age,  diabetes,  and  high  risk  stratification
according to EuroSCORE-II. Of the 275 elderly patients with severe MR included in
this study, 75 (27.27%) did not undergo surgery.
A database from the University Centre of Liepzig, Germany was examined and
assessed  to  identify  all  patients  aged  >  70  years  who  underwent  MV  surgical
procedures between 1999 and 2009. In 97% of the 2503 patients, MR was the primary
indication for operation[64]. MV repair was performed in 64%. Mortality rate at 30 days
was  3.1%,  and  survival  at  5  years  was  55.2%.  Coronary  revascularization  was
associated with an early and long-term poorer outcome. Several  factors,  such as
diabetes,  chronic  obstructive  lung  disease,  left  ventricular  function  <  30%,
preoperative  hemodialysis,  presence  of  endocarditis,  MVR,  concomitant  TV
procedures,  urgent  or  emergent  procedures,  aortic  procedures,  aortic  valve
replacement, and CABG, were independently related younger late death[64].
A recent retrospective study by Silashi et al[65] reviewed the results after MV surgery
in elderly patients treated over the past  20 years.  Excluded from the study were
patients  with repeat  cardiac surgery,  endocarditis,  and concomitant  aortic  valve
replacement.  Of  1776  patients  with  MV disease,  341  were  aged ≥  75  years.  Two
hundred and twenty-one underwent MV-repair and 120 MVR. One hundred thirty-
five patients had concomitant coronary artery bypass grafting (39.6%).  Fifty had
tricuspid valve (TV) surgery (14.7%). Thirty-day mortality associated with MV repair
was  5.4% vs  9.2% for  MVR (P  =  0.26).  Concomitant  CABG was more  frequently
performed in patients undergoing MV-repair (43.9% vs 31.7%, P = 0.03). In 27 patients,
planned MV-repair was converted to MVR, mainly after invasive inspection of the
MV. Moderate/severe MR was observed at follow-up in 15 cases after MV-repair
(6.8%), of which four needed reintervention. After MVR, significant MR was observed
in only 3 cases (2.5%). Overall 1- and 5-year survival was 90.7% and 74.2% vs 81.3%
and 61.0%, respectively (P < 0.01).
In a propensity adjusted analysis of outcomes after MV surgery in patients aged >
80 years (mean age 83 years), overall operative mortality was 11% after MV-repair in
comparison to 18.9% for MVR[66]. It must be underlined that this study also included
patients with endocarditis (1.8% in MV-repair and 13.7% in MVR) and ischemic MV
disease (32.2% in MV-repair).
Included in a meta-analysis by Shang et  al[67]  were seven observational clinical
studies published after 2000 comparing MVP and MVR in the elderly (aged 70 years
or  older).  Overall,  1809  patients  were  considered.  Thirty-day  mortality  was
significantly lower after MV repair (RR: 0.40, 95%CI: 0.25–0.64). Moreover, repair was
associated  with  length  of  postoperative  hospital  stay  and  less  postoperative
complications in comparison to MVR. Finally long-term (1- and 5-year survival) were
higher in MV-repair.
Patients at high-prohibitive risk for surgery may benefit, when technically feasible,
by percutaneous interventional treatment. MitraClipTM therapy is at present the most
widely used technique. The device allows for building a bridge between the anterior
and posterior mitral leaflet thus mimicking the surgical technique of the Alfieri stitch.
In patients treated for degenerative MR, despite good periprocedural results, the rate
of recurrent severe MR after MitraClipTM therapy has been reported close to 55% at 12
mo[68]. The need for re-operations may exceed 20% at 4 years of follow-up[69].
Failure of MitraClipTM procedures may be related to the absence of concomitant
annuloplasty. Failed MitraClipTM procedures may complicate eventual future MV-
repair. In particular when treatment included more than one clip valves, which are
often  not  repairable.  Further  techniques,  such  as  transcatheter  MV-in-ring
implantation, may be considered in selected cases after failure on MV repair.
Surgery  must  be  considered the  initial  “gold  standard”  treatment  for  elderly
patients with degenerative MR and acceptable surgical risk should be considered. A
multidisciplinary “Heart Team” should discuss the patient’s condition and various
treatment opportunities. New interventional treatment options may be considered for
symptomatic high risk patients.
TV
Tricuspid regurgitation (TR) is  the second most common VHD after MR with an
incidence of 1.2% to 1.5% in the general population[1,2]. The prevalence increases with
age and in particular in females. In the group of 70 to 83 year-olds, incidence is 5.6%
in women as compared to 1.5% in men[23]. Severe TR is associated with higher 1-year
mortality and poorer outcomes independent of age and other comorbid conditions[70].
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Primary valve disease accounts for 25% of TR. This is more common in younger
patients  suffering  from  anatomic  valve  abnormalities  (congenital,  rheumatic,
neoplastic, traumatic, infective endocarditis, and endomyocardial fibrosis). Other
causes of TR are lead implantation for pacing or leaflet damage due to RV biopsy[71].
In elderly subjects, functional or secondary TR due to left heart disease, often MR or
AS, is by far the more common etiology of TR[70]. TR secondary to left heart valve
disease is  often associated with poor prognosis and difficult  therapeutic choices.
Pulmonary hypertension, right ventricular infarction, chronic right ventricular pacing,
and history of AF are other common causes of secondary TR. The term ‘‘functional’’
may be misleading for TV disease. As with the MV, annular dilatation of the tricuspid
annulus and/or dislocation of papillary muscles plays just as important of a role in
causing  valve  malfunction[72].  Annular  dilatation  occurs  along  the  anterior  and
posterior TV leaflet implantation; therefore, the annulus becomes more circular and
planar. Geometrical abnormalities may be different between secondary TR and the so-
called “idiopathic TR,” commonly attributed to ageing and AF[73,74]. In idiopathic TR,
basal RV dilatation with relatively normal RV length and marked annular dilatation
but with normal tenting height of leaflets is  commonly observed. Where there is
functional  TR in  patients  with  pulmonary hypertension,  there  is  a  spherical  RV
deformation,  with less  evident  annular  dilation but  significantly greater  tenting
height.  These  morpho-functional  differences  have  significant  implications  for
treatment.
Treatment
A  conservative  (no  touch)  approach  to  TR  was  proposed  in  the  1960s.  It  was
conceivable that the hemodynamic improvement related to the correction of the left-
sided valve disease would result in a decrease of secondary TR. The experiences that
followed,  however,  demonstrated  that  regression  of  TR  is  not  the  rule,  and
regurgitation may further increase in particular when the mitral and/or aortic valve
diseases are not completely or adequately resolved during surgery. Moreover, it must
be stressed that an isolated severe TR is now increasingly recognized even in patients
with normal left heart valve function after either MV annuloplasty or replacement.
The degree of right ventricular dysfunction indicated by annular dilatation may be
related to impaired regression of further increased degree of valve regurgitation.
Preoperative  evaluation  may  give  information  whether  TR  will  resolve  after
successful mitral surgery. Four hundred and thirteen patients with rheumatic heart
disease,  who  did  not  have  preoperative  severe  TR,  underwent  MVR  without
concomitant TV repair and were then followed for a median period of 13 years[75].
Forty-six patients (11.1%) had new severe TR. Independent predictors for new severe
TR were preoperative moderate TR (HR 2.401; P = 0.008) and AF (HR 2.119; P = 0.018).
Patients with new severe TR had larger right ventricles and higher pulmonary artery
pressures on echocardiography.
Right ventricular failure is associated with a higher surgical mortality (from 5% to
11%  and  from  8%  to  22%  during  follow-up)[76].  Preoperative  right  ventricular
dysfunction and persisting TR are associated with a minor relief of symptoms and an
impaired cardiac output response to exercise after correction of valve diseases.
Although it has been suggested that functional TR may be untreated in patients
with a significant predictable decrease in the pulmonary resistance, at present we
have no reliable methods to predict reversibility of the TR after correction of the left
heart valve dysfunction. Moreover, methods of measuring and quantifying the degree
of  TR  are  still  not  reliable  and  repeatable.  The  clinical  assessment  may  add
information to echocardiography. Finally, there is no satisfactory method to assess
true right ventricular function.
Often,  in  elderly  patients  with  long  standing  disease,  TR  frequently  poses  a
challenging treatment dilemma[77]. Severe TR may be tolerated for many years and
sometimes  managed  conservatively  until  severe  right  heart  failure  and  ascites
develop. It is then often too late for correction since any therapy comes with extremely
high  risk,  with  unacceptable  operative  mortality.  Moreover,  the  likelihood  of
functional  recovery  is  poor.  American  College  of  Cardiology/American  Heart
Association guidelines do not give any Class I indications for isolated TV surgery[42].
Operative risk is high in these patients with a mortality rate of 7.9% at 30 days. Age is
an independent predictor according to multivariable analysis.  Reduction of right
ventricle  afterload  after  treatment  of  a  left-sided  valve  lesion  may  lead  to  an
improvement, even if often unpredictable, of severe TR. TV repair during left sided
surgery does not appreciably increase the risks of surgery. TR repair is currently
recommended in patients undergoing left-sided valve surgery. Effects of depressed
right ventricular function on results of TV repair were examined by Subbotina et al[78].
Eighty-two out of 191 patients (43%) had decreased tricuspid annular plane systolic
excursion (TAPSE) (13.3 ± 3.3 mm vs 20.2 ± 4.9 mm; P<0.001). In both groups, 91%
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underwent ring annuloplasty. Patients with depressed right ventricular function had
a higher incidence of low cardiac output syndrome after surgery (10% vs 27%, P=
0.005) and a higher early mortality. Functional improvement, expressed as change in
NYHA class, was more evident in patients with preserved right ventricular function.
Of 173 patients who underwent MV surgery and radiofrequency ablation of AF, only
age  and  concomitant  TV  repair  were  independently  associated  with  mortality
according to multivariate analysis[79].
In the last years, numerous percutaneous transcatheter repair and replacement
devices were developed to treat this large group of high surgical risk patients. To
improve prognosis in severe TR, an earlier diagnosis and referral for treatment are
essential, as are a better understanding of the different stages of disease and potential
treatment options, proven safe and efficacious percutaneous options, and an evidence
base for earlier surgical or percutaneous intervention of significant TR, irrespective of
symptoms.  The  use  of  MitraClipTM  in  the  tricuspid  position  is  associated  with
unpredictable results. Date reported from a recent registry showed a > 50% reduction
in effective regurgitant orifice area after treatment with MitraClipTM. The procedure
was associated with significant clinical improvement with decrease in the NYHA
functional class and longer 6 minute walking distance[80]. Other transcatheter therapies
are being tested in feasibility trials.  Among these the Trialign system (Mitralign,
Tewksbury, Massachusetts, United States) that mimics the surgical Kay annuloplasty
via a pair of pledgeted sutures delivered percutaneously through the right internal
jugular vein.
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